Russian pharmaceutical company Binnopharm Group (part of ФАЛ Sistema) has launched Alfaxim, the first Russian-made drug with rifaximin as the active ingredient, the press service of the pharmaceutical manufacturer reports. The drug is produced at the Alium plant, the company’s production site near Moscow.
The company notes that today in Russia, according to various data, more than 11 million patients are in need of a modern antibacterial therapy for digestive system diseases.
“We have become the first Russian company to successfully introduce rifaximin to the market, making this modern antibiotic more accessible to consumers and reducing patients’ dependence on foreign product supplies,” said Rustem Muratov, CEO of Binnopharm Group.
He noted that one of the key areas in the company’s portfolio is gastroenterology, with more than 20 prescription and over-the-counter drugs.
It also includes Neobutin, an antispasmodic agent with a prokinetic effect; Gastrostat, a gastroprotector; Urdoxa, a hepatoprotector, drugs that have leading positions in their target markets, as well as other drugs for prevention and treatment of diseases of the gastrointestinal tract, liver, and gallbladder.
